NMR Evidence for the 8.5 K Phase Transition in Americium Dioxide
摘要:
We report here the first NMR study of americium dioxide (AmO2). More than 30 years ago, a phase transition was suggested to occur in this compound at 8.5K based on magnetic susceptibility data, while no evidence had been obtained from microscopic measurements. We have prepared a powder sample of (AmO2)-Am-243 containing 90 at. % O-17 and have performed O-17 NMR at temperatures ranging from 1.5 to 200 K. After a sudden drop of the O-17 NMR signal intensity below 8.5 K, at 1.5 K we have observed an extremely broad spectrum covering a range of similar to 14 kOe in applied field. These data provide the first microscopic evidence for a phase transition as a bulk property in this system. In addition, the O-17 NMR spectrum has been found to split into two peaks in the paramagnetic state, an effect which has not been reported for actinide dioxides studied up to now. We suggest that the splitting is induced by self-radiation damage from the alpha decay of Am-243.
Rate constants for the reaction of O2+ with NO from 300 to 1400 K
摘要:
The rate constants for the charge transfer reaction of O2+ with NO have been measured from 300 to 1400 K using a high temperature flowing afterglow. The current results agree well with the previous flowing afterglow studies made at temperatures up to 900 K. The rate constants have no significant temperature dependence over the entire temperature range. The rate constants are in good agreement with the previous flow drift tube measurements at the same translational temperatures. Any dependence of the rate constant on internal energy is therefore small.
作者:Skip Williams、Meghann F. Campos、Anthony J. Midey、Susan T. Arnold、Robert A. Morris、Albert A. Viggiano
DOI:10.1021/jp012929r
日期:2002.2.1
was developed to study the negativeion chemistry of ozone in the gasphase. Rate constants and product ion branching fractions are reported for 17 negative ion-molecule reactions involving ozone (O 3 ). This is the most comprehensive set of O 3 reactions with negativeions to date. The reactions proceed primarily through charge transfer and O atom transfer. The reaction rate constants for O - , O
开发了一种新型臭氧源来研究臭氧在气相中的负离子化学。报告了 17 个涉及臭氧 (O 3 ) 的负离子分子反应的速率常数和产物离子支化分数。这是迄今为止最全面的与负离子的 O 3 反应。反应主要通过电荷转移和O原子转移进行。O - 、O 2 - 和 OH- 的反应速率常数很大,大约等于基于平均偶极子取向理论的 Su-Chesnavich 方程给出的热能捕获速率常数。负离子 NO 2 - 、CO 4 - 、SF 6 - 和 PO 2 - 的反应性稍差,以大约 20-50% 的热捕获率反应。氢氟烃离子 CF 3 - 和 C 2 F 5 - 以 80% 的热捕获率反应,F- 是形成的主要产物离子。发现 NO 3 - 、CO 3 - 、PO 3 - 、CF 3 O - 、F - 、Cl- 和 Br- 在速率常数 < 5 × 10 - 1 2 cm 3 s - 1 时不发生反应,即目前我们使用这种臭氧源的设备的检测限。观察到
Temperature dependence of ternary rate coefficients for the (CO)n−1++2CO⇌(CO)n++CO reaction, and the role of isomers for the growth of larger (CO)n+ clusters
作者:S. Schlemmer、A. Luca、J. Glosik、D. Gerlich
DOI:10.1063/1.1451247
日期:2002.3.15
Ternaryratecoefficients for the title reaction have been measured using a rf 22-pole ion trap in the temperature range 65–300 K. For the formation of dimers, the ternaryratecoefficient, k3, follows the power law 2.3×10−28 cm6/s×(300 K/T)m, with m=1.6±0.2 over the full temperature range of the experiment. This result is in good agreement with previous measurements at higher temperatures and also
Substituted Bicyclic Aromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
申请人:FRANK Robert
公开号:US20130029995A1
公开(公告)日:2013-01-31
Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).
COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER
申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20160175306A1
公开(公告)日:2016-06-23
The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.
The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.